Patient Information Leaflets (PILs)
These Patient Information Leaflets (PILs) are specially written by the British Association of Dermatologists (BAD).
The BAD has been awarded The Information Standard certification for the process it employs to develop information products aimed at the general public, which include PILs, Sun Awareness Campaign materials, and other information products.
The BAD shall hold responsibility for the accuracy of the information published, and neither the scheme operator nor the scheme owner shall have any responsibility for costs, losses, or direct or indirect damages or costs arising from inaccuracy of information or omissions in information published on the website on behalf of the BAD.
There are thousands of different skin complaints, therefore, the focus of the British Association of Dermatologists' PILs production is on the most common, rarest or debilitating skin conditions.
The offer to provide details of source materials used to inform the British Association of Dermatologists' PILs is for instances where the advice provided in the PILs does not reflect local practice and therefore evidence supporting said advice needs to be produced. It is not an offer to conduct literature searches or supply bibilographic materials for your own research.
Kaposi’s sarcoma (KS) is a growth of the cells from the inner lining of blood vessels. It is linked to infection with Human Herpes virus type 8 (Kaposi sarcoma herpes virus, HHV8), and impairment of the immune system. It is named after Dr Moritz Kaposi, a Hungarian dermatologist, who first described it in 1872. ‘Sarcoma’ (from ancient Greek ‘flesh’) means a cancerous growth of the soft tissues under the skin and is present in other organs. Kaposi’s sarcoma is actually not a cancer, but rather a tissue-overgrowth.
Kaposi’s sarcoma can be mild, only affecting the skin, or more extensive with involvement of lymph nodes and internal organs such as the lungs or digestive system, in which case it may be fatal.